ERBB4 inhibitors and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10045990-B2
Application number	US-201615555241-A
Country	US
Kind code	B2
Filing date	Mar 2, 2016
Priority date	Mar 4, 2015
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

Disclosed herein are methods of treating diseases that exhibit over-activation of the ERBB4 pathway, such as breast cancer and lung cancer. The method comprises administering to a subject having a disease that exhibits over-activation of the ERBB4 pathway and a gene expression profile consistent with an ERBB4-sensitive profile a therapeutically effective amount of an ERBB4 inhibitor, wherein the disease is effectively treated. Gene expression profiles of ERBB4-sensitive cells and microarrays suitable for protein-tyrosine kinases are also provided.

First claim

We claim:

1. A method of treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of an ERBB4 inhibitor to a subject having ERBB4 overexpressing cancer cells, wherein the ERBB4 overexpressing cancer cells are negative for expression of Bruton's tyrosine kinase (BTK), whereby the ERBB4-overexpressing/BTK-negative cancer cells are treated.

2. The method of claim 1 , wherein the ERBB4 inhibitor is ibrutinib.

3. The method of claim 1 , wherein the ERBB4 inhibitor is AST1306.

4. The method of claim 1 , wherein the cancer is selected from the group consisting of breast cancer, lung cancer, endometrial cancer, melanoma, colon cancer, gastric cancer, prostate cancer, ovarian cancer, glioma, and astrocytoma.

5. The method of claim 1 , wherein said subject is human.

6. A method for identifying and treating a patient disposed to respond favorably to an ERBB4 inhibitor therapy, the method comprising: (a) detecting ERBB4 overexpression in cancer cells in tissue sample from the patient, wherein the ERBB4 overexpressing cancer cells are negative for expression of Bruton's tyrosine kinase (BTK); (b) assessing levels of DKK1 and Wnt5A levels in the ERBB4-overexpressing/BTK-negative cancer cells, wherein a positive ratio of DKK1 to Wnt5A in a cancer cell from said sample indicates that the patient will benefit from ERBB 6 4 inhibitor therapy; and (c) treating the patient with an ERBB4 in an amount effective to treat the cancer.

7. The method of claim 6 , wherein the ERBB4 inhibitor is ibrutinib.

8. The method of claim 6 , wherein the ERBB4 inhibitor is AST1306.

9. The method of claim 6 , wherein said patient is a human patient.

Assignees

• Univ Arizona State

Inventors

• Festa Fernanda
• Labaer Joshua
• Park Jin
• Rauf Femina

Classifications

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title